Clinical Trial Update: Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 trial evaluating Omega-3 fatty acid with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia has been terminated; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Omega-3 Fatty Acid (omega-3 fatty acids)
• Tyrosine kinase inhibitors

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Chronic Myeloid Leukemia, Chronic Phase | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-07-01